{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"8.1","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"ORR was determined by local, Investigator assessment for each tumor assessment and defined as responses of CR+PR ≥ 16 weeks. FAS","dispersionType":"95% Confidence Interval","groups":[{"description":"LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.","id":"OG000","title":"Ribociclib 600 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline and ≥ 16 weeks up to approximately 36 months","title":"Overall Response Rate (ORR) ≥ 16 Weeks. FAS","type":"PRIMARY","unitOfMeasure":"participant"}